Latest Healthcare News

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.

Oneview Healthcare PLC reported a 21% increase in total revenue to €12 million for the year ended 31 December 2025, driven by growth in recurring revenue and customer expansion. Despite this, the company’s loss after tax widened to €12.6 million, reflecting ongoing investment and cost pressures.

Oakridge International Limited has reported a striking turnaround in its half-year results, posting a profit after tax of $172,239 against a prior loss, driven by strong sales and product innovation in healthcare technology.

Cyclopharm Limited has completed the initial phase of a $14 million share placement, issuing nearly 9.5 million shares at 95 cents each, with the remaining shares set for issuance later this month.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

Arena REIT reported a robust half-year performance for HY2026, with net profit rising to $110 million and earnings per security up 5.4%. The company reaffirmed its FY2026 distribution guidance, underpinned by strong rental growth and disciplined capital management.

Arena REIT has reported a robust HY2026 financial performance, with net operating profit rising 9% and statutory net profit surging 202%. The REIT’s active portfolio management and development pipeline underpin its confidence in sustained growth.

Arena REIT reported a remarkable 202% jump in net profit for the half-year ending December 2025, driven by significant property revaluation gains and steady rental income growth. Distributions rose 5%, supported by an expanded and fully leased portfolio of early learning and healthcare properties.

Rhythm Biosciences has taken a significant step toward commercialising its ColoSTAT blood test for colorectal cancer by enrolling the first physician in its Access Program, marking the transition from clinical trials to routine clinical use.

TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.

Bailador Technology Investments reports a strong HY26 with a 9.5% post-tax NTA per share increase to $1.76 and declares a fully franked interim dividend of 3.9 cents. The technology-focused portfolio saw revenue surge 42% to $673 million, underpinned by robust cash realisations including a $25 million partial sale of SiteMinder.